X4 slash­es pipeline, lays off staff just three weeks af­ter net­ting a $55M PIPE

Not even a PIPE fi­nanc­ing could save X4 Phar­ma­ceu­ti­cals from en­act­ing lay­offs and trim­ming its pipeline.

The Boston biotech re­vealed Wednes­day af­ter­noon that it would down­size its re­search to fo­cus on its lead pro­gram, ma­vorix­afor, and lay off about 20% of its staff. The move comes less than three weeks af­ter X4 pulled to­geth­er a $55 mil­lion PIPE and amend­ed a loan fa­cil­i­ty with Her­cules Cap­i­tal to re­duce cash burn.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER